TABLE 1.
Patient demographics
| Demographic | Total |
Concomitant immunosuppressive therapy |
|
|---|---|---|---|
| Yes | No | ||
| Patients, n | 117 | 104 | 13 |
| Women, n (%) | 62 (53) | 52 (50) | 10 (77) |
| Caucasian, n (%) | 115 (98.3) | 102 (98.1) | 13 (100) |
| Mean age at first infliximab infusion, years (95% CI) | 36.5 (34.3–38.7) | 36.1 (33.8–38.3) | 40.0 (32.8–47.4) |
| Mean time from Crohn’s disease diagnosis to first infliximab infusion, years (95% CI) | 11.5 (9.9–13.0) | 11.4 (9.8–13.1) | 12.2 (8.0–16.4) |
| Anatomical distribution, n (%) | |||
| Ileal | 42 (35.9) | 37 (35.6) | 5 (38) |
| Ileocolonic | 37 (31.6) | 31 (29.8) | 6 (46) |
| Colonic | 38 (32.5) | 36 (34.6) | 2 (15) |
| C-reactive protein, mg/L (mean [95% CI]) | 16.6 (12–21.2) | 16.6 (11.6–21.6) | 16.4 (1.3–31.5) |
| Concomitant immunosuppressive prescriptions, n (%) | 104 (89) | 104 (100) | 0 (0) |
| Azathioprine/6-mercaptopurine, n (%) | 80 (68.4) | 80 (77) | – |
| Methotrexate, n (%) | 24 (20.5) | 24 (23) | – |